Search

Your search keyword '"Welty F"' showing total 84 results

Search Constraints

Start Over You searched for: Author "Welty F" Remove constraint Author: "Welty F"
84 results on '"Welty F"'

Search Results

1. Salivary glucose concentration exhibits threshold kinetics in normal-weight, overweight, and obese children

2. Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial

3. Evaluation of the effect of sodium–glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial

4. Evaluation of the effects of sodium–glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial

7. Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA

8. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk The CARMELINA Randomized Clinical Trial

11. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

12. Relative effects of statin therapy on stroke and cardiovascular events in men and women: Secondary analysis of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study

13. Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study

15. Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial

23. Human apolipoprotein A-I kinetics within triglyceride-rich lipoproteins and high density lipoproteins.

32. Women and cardiovascular risk.

33. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

34. Reasons for higher in-hospital mortality >24 hours after percutaneous transluminal coronary angioplasty in women compared with men.

37. The Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Cardiovascular Homeostasis: A Non-Systematic Literature Review.

38. Effect of Targeting Inflammation With Salsalate: The TINSAL-CVD Randomized Clinical Trial on Progression of Coronary Plaque in Overweight and Obese Patients Using Statins.

39. Unhealthy Phenotype as Indicated by Salivary Biomarkers: Glucose, Insulin, VEGF-A, and IL-12p70 in Obese Kuwaiti Adolescents.

40. Continuous Metabolic Syndrome Scores for Children Using Salivary Biomarkers.

41. Metabolic disease risk in children by salivary biomarker analysis.

42. Measuring noncalcified coronary atherosclerotic plaque using voxel analysis with MDCT angiography: a pilot clinical study.

44. Women and cardiovascular risk.

45. Effects of a National Cholesterol Education Program Step II Diet on apolipoprotein A-IV metabolism within triacylglycerol-rich lipoproteins and plasma.

46. Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial.

47. Cardiovascular disease and dyslipidemia in women.

48. Effects of ApoE genotype on ApoB-48 and ApoB-100 kinetics with stable isotopes in humans.

49. Stable isotope turnover of apolipoproteins of high-density lipoproteins in humans.

50. Optimal management of non-ST segment elevation myocardial infarction remains unclear.

Catalog

Books, media, physical & digital resources